AstraZeneca fails to meet target endpoints in Phase II bladder cancer trial Medical Dialogues Bureau10 March 2020 4:00 AM GMTUSA: The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not me...
